EFSA Approves Cholesterol Management Claims for Plant Sterols/Stanols
Phytosterols are one of the few winners in EFSA's latest round of health claims opinions.
Among the many rejections of Article 13.1 claims published by the European Food Safety Authority (EFSA; Parma, Italy) on October 19, there were some notable winners-one being plant sterols and stanols.
EFSA’s Panel on Dietetic Products, Nutrition, and Allergies (NDA) confirmed a cause and effect relationship between plant sterols and stanols and blood cholesterol reduction. The NDA panel stated that wording claims like “Plant sterols/stanols help to maintain normal blood cholesterol levels,” and “Plant sterols/stanols contribute to the maintenance of normal blood cholesterol levels” are supported by the scientific evidence that was provided to the panel.
In order to validate the use of such claims, the panel decided on a minimum required content of 0.8 g of sterols/stanols per serving of a food.
The panel also warned that consumption of the ingredients might not be nutritionally appropriate for pregnant or breastfeeding women and children under five years old.
To download EFSA’s full document on plant sterols and stanols, click here.
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.
